EquiCord
EquiCord is a Spanish veterinary biotechnology company that develops EMA-authorized stem cell medicines (HorStem for horses, DogStem for dogs) derived from equine umbilical cord mesenchymal stem cells, selling directly and through distributors including Dômes Pharma Group to veterinary clinics across Europe.
- Company typePrivate
- Founded2012
- HeadquartersAlcorcón, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EquiCord does
EquiCord is a veterinary biotechnology company that develops and manufactures stem cell-based prescription medicines derived from equine umbilical cord mesenchymal stem cells (EUC-MSCs). Founded in 2012 and headquartered in Alcorcón, Madrid, the company operates GMP-certified manufacturing facilities (over 500m² including a 100m² GMP production room) where more than 30 quality controls are performed in alignment with European Pharmacopoeia standards. EquiCord's core technology uses a proprietary, trade-secret-protected process to extract and expand MSCs from equine umbilical cord tissue collected via a non-invasive on-farm method, with a patented disinfection protocol. Cells are packaged as fresh, ready-to-use injectable suspensions storable in standard refrigerators, eliminating thawing or ultra-low temperature handling at the clinic.
EquiCord has commercialized two EMA-authorized medicines: HorStem (EMA 2019) for reduction of lameness associated with mild to moderate degenerative joint disease in horses, and DogStem (EMA and UK 2022) for pain and lameness associated with canine osteoarthritis, with DogStem positioned as the world's first stem cell medicine for canine OA. The company is also running three additional clinical trials exploring indications including inflammatory bowel disease, chronic renal failure, atopic dermatitis, ophthalmic problems, and wounds.
The business model centers on prescription veterinary medicine distribution to equine and companion animal veterinary clinics across Europe. HorStem is sold direct from EquiCord's GMP factory to European clinics through a network of distributors (Provet, Nvet, Grovet, Vetviva, Novidia), while DogStem is commercialized in 15+ countries via a flagship partnership with Dômes Pharma Group. Pricing is not publicly disclosed. The legal entity is EquiCord, SL, a Spanish private limited company with approximately 14 employees.
EquiCord firmographics
Firmographics- Name
- EquiCord
- Legal name
- EquiCord, SL
- Website
- https://equicord.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EquiCord is a Spanish veterinary biotechnology company that develops EMA-authorized stem cell medicines (HorStem for horses, DogStem for dogs) derived from equine umbilical cord mesenchymal stem cells, selling directly and through distributors including Dômes Pharma Group to veterinary clinics across Europe.
- Ownership category
- akta.pro rank
EquiCord industry classification
Industry- Product category
- Veterinary Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)
- akta.pro secondary industries
- Equine Therapeutics (Rx) (HLAMAEAC), Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing) (HLAMANAI), Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology) (HLAMAIAH)
Keywords
Where EquiCord is headquartered
LocationHeadquarters
- HQ city
- Alcorcón
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
EquiCord business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Veterinary Pharmaceutical Products: Revenue from selling EMA-authorized veterinary stem cell medicines (HorStem for horses, DogStem for dogs) to veterinarians and veterinary clinics across Europe. Products are prescription-only veterinary medicines sold through direct distribution and channel partners.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
EquiCord product offering
Product offeringCore offering
EquiCord develops, manufactures, and commercializes EMA-authorized injectable veterinary medicines derived from equine umbilical cord mesenchymal stem cells (EUC-MSCs). Its two commercial products—HorStem for equine osteoarthritis/lameness and DogStem for canine osteoarthritis—are prescription-only biologics produced at a GMP facility in Madrid and distributed to veterinarians and veterinary clinics across Europe. The company leverages a proprietary trade-secret manufacturing process, including a patented on-farm disinfection step, to deliver fresh, ready-to-use cell therapy doses that do not require thawing or ultra-low temperature storage.
Product overview
EquiCord is a veterinary advanced therapy company specializing in stem cell-based medicines derived from equine umbilical cord mesenchymal stem cells (EUC-MSCs). The company offers two EMA-authorized products: HorStem (for equine osteoarthritis/lameness, 2019) and DogStem (for canine osteoarthritis, 2022). Both products are ready-to-use injectable suspensions that leverage the company's proprietary non-invasive cell extraction technology and GMP manufacturing facilities in Spain. The products work through immunomodulatory and anti-inflammatory mechanisms to reduce pain, lameness, and cartilage degradation without the side effects of conventional treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- HorStem HorStem is an EMA-authorized injectable veterinary prescription medicine containing 15 million equine umbilical cord mesenchymal stem cells, indicated for reduction of lameness associated with mild to moderate degenerative joint disease (osteoarthritis) in horses. It is sold to equine veterinarians and veterinary clinics as a fresh, ready-to-use formulation that requires no thawing or ultra-low temperature storage.
- DogStem DogStem is an EMA-authorized injectable veterinary prescription medicine containing 7.5 million equine umbilical cord mesenchymal stem cells, indicated for the reduction of pain and lameness associated with canine osteoarthritis. It is sold to companion-animal veterinary clinics as a ready-to-use formulation stored in standard veterinary refrigerators, distributed through the Dômes Pharma Group partnership across 15+ countries.
Quantifiable outcome
- 72% of treated horses reduced lameness to absence or inconsistent lameness (≤grade 1)
- +5 more outcomes
Companies that use EquiCord
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
EquiCord technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
EquiCord partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship and core.
- Dômes Pharma GroupflagshipEquiCord partnered with Dômes Pharma Group to distribute DogStem - the world's first injectable stem cell formulation for canine osteoarthritis treatment. The independent family group has been in the pharmaceutical industry since 1947, has 400 employees at 5 sites in France, England and Germany, and distributes to more than 15 countries.
- ProvetcoreEuropean distributor for HorStem veterinary medicine products.
- NvetcoreEuropean distributor for HorStem veterinary medicine products.
- GrovetcoreEuropean distributor for HorStem veterinary medicine products.
- VetvivacoreEuropean distributor for HorStem veterinary medicine products.
- NovidiacoreEuropean distributor for HorStem veterinary medicine products.
Scale indicators9 records
Recent moves6 records
Expansion highlights4 records
EquiCord competitors and assessment
Company assessmentBroad incumbents
- Virbac: Global veterinary pharmaceutical company with significant companion-animal and equine portfolios. Comparable to EquiCord as an EU-headquartered animal pharma competitor serving equine and canine practices.
- Ceva Santé Animale: Multinational animal-health group active across pharmaceuticals, biologics and vaccines for companion and production animals. Comparable to EquiCord as a competing EU-based animal biologics company with broader species coverage.
- Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company with strong equine and companion-animal product lines. Comparable to EquiCord as a competing equine/canine pharma, though focused on small molecules rather than stem-cell biologics.
- Elanco Animal Health: Large animal-health company offering pharmaceuticals and biologics across companion and farm animals. Comparable to EquiCord as a competing veterinary biologic manufacturer, with broad portfolio and global commercial reach.
- Zoetis: World's largest animal-health company with deep equine and companion-animal pharmaceutical, biologic and diagnostics portfolios. Comparable to EquiCord as a competing animal biologic manufacturer, with vastly greater R&D and commercial resources.
- Boehringer Ingelheim Animal Health: Major animal-health division of Boehringer Ingelheim with vaccines, parasiticides and therapeutics for companion and production animals. Comparable to EquiCord as a large animal biologics competitor with capability to enter equine and canine regenerative medicine.
- Vetoquinol: Global veterinary pharmaceutical company with broad equine and companion-animal portfolios. Comparable to EquiCord as an animal-health pharma serving equine veterinarians, but operates at much larger scale and across many therapeutic categories.
Direct peers
- MediVet Biologics: Animal health company offering in-clinic stem cell kits and regenerative therapies for horses, dogs and cats. Comparable to EquiCord in the stem-cell veterinary niche, though focused on adipose-derived point-of-care kits rather than EMA-approved allogeneic drugs.
- VetStem Biopharma: US-based pioneer of autologous adipose-derived stem cell therapy for dogs, cats and horses. Direct competitor to EquiCord in the veterinary regenerative medicine category, though using a different cell source and frozen/autologous delivery model.
- Ardent Animal Health: Provider of platelet-rich plasma and stem cell therapies for equine and companion animals. Closely comparable to EquiCord in target species and regenerative-medicine modality, competing for the same veterinary hospital channel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
EquiCord social profiles
Digital presenceEquiCord compliance and trust
Trust signalCompliance1 record
EquiCord financial estimates
Financial estimateRevenue estimate
Valuation estimate
EquiCord leadership team
Management profileNumber of profiles
Profiles7 records
EquiCord funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EquiCord M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EquiCord
What does EquiCord do?
EquiCord develops, manufactures, and commercializes EMA-authorized injectable veterinary medicines derived from equine umbilical cord mesenchymal stem cells (EUC-MSCs). Its two commercial products—HorStem for equine osteoarthritis/lameness and DogStem for canine osteoarthritis—are prescription-only biologics produced at a GMP facility in Madrid and distributed to veterinarians and veterinary clinics across Europe. The company leverages a proprietary trade-secret manufacturing process, including a patented on-farm disinfection step, to deliver fresh, ready-to-use cell therapy doses that do not require thawing or ultra-low temperature storage.
Is EquiCord a public or private company?
EquiCord is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EquiCord founded?
EquiCord was founded in 2012. It employs 11 to 50 people.
Where is EquiCord based?
EquiCord is headquartered in Alcorcón, Spain, in the Europe region.
How does EquiCord make money?
One revenue line is on record: veterinary Pharmaceutical Products.
Who are EquiCord's main competitors?
Broad incumbents on record are Virbac, Ceva Santé Animale, Dechra Pharmaceuticals, Elanco Animal Health, Zoetis, Boehringer Ingelheim Animal Health and Vetoquinol. Direct peers are MediVet Biologics, VetStem Biopharma and Ardent Animal Health.
Does EquiCord have an API?
No public API is recorded for EquiCord.
What industry is EquiCord in?
EquiCord's product category is Veterinary Biologics. Its primary akta.pro industry code is HLAMAEAK, Biologics & Immunotherapies (Non-vaccine), with a secondary code of HLAMAEAC, Equine Therapeutics (Rx). Its NAICS code is 325414 and its SIC code is 2836.